|Bid||0.1550 x 0|
|Ask||0.1600 x 0|
|Day's Range||0.1600 - 0.1650|
|52 Week Range||0.0400 - 0.3500|
|Beta (5Y Monthly)||1.83|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Vancouver, British Columbia--(Newsfile Corp. - April 7, 2021) - Voyageur Pharmaceuticals (TSXV: VM) (OTC: VYYRF) has received two license approvals from Health Canada for its MultiX barium sulfate powder. The two licenses cover both oral and rectal applications. MultiX is specifically designed for oral suspension and indicated for use in single contrast radiographic examinations of the esophagus, stomach, duodenum and small bowel to visualize the gastrointestinal tract in adult and pediatric patients.MultiX, along with ...
Vancouver, British Columbia--(Newsfile Corp. - February 17, 2021) - Voyageur Pharmaceuticals (TSXV: VM) (OTCQB: VYYRF) has received approval from Health Canada for two of the company's barium contrast products.SmoothX, the company's barium radiographic contrast suspension specifically formulated for computed tomography procedures, commonly known as CT Scans, along with HDX Ba, a barium radiographic contrast powder specifically formulated for Fluoroscopy barium X-Ray procedures that can also be used for CT Scans, have both received Health ...
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...